HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA List Of Supplement Formulation Taboos Adds Ephedra-Like Ingredient

This article was originally published in The Tan Sheet

Executive Summary

CFSAN warns seven companies about products marketed as supplements with labeling listing methylsynephrine as a dietary ingredient. The center also warned two of the firms their products contained other ingredients FDA previously began forcing off the market, DMAA and DMBA.

You may also be interested in...



DMAA, Other Stimulants Cast Shadow Over FDA Supplement Regulation – Study

Six workout and weight loss brands contained DMAA and three other stimulants, according to a study in the Journal Clinical Toxicology. Researchers concluded consumers must be informed of risk so they know to check labels for three substances that indicate the presence of the stimulants.

Second Warning, Second Unsafe Ingredient For Total Body Nutrition

FDA's Sept. 28 warning letter to Total Body Nutrition also noted violative claims and labeling for its products marketed with the TBN brand and listed GMP problems. First methylsynephrine in 2016, now DMAA land firm on FDA enforcement radar.

Supplement Industry Stained By Criticism Due Irresponsible Firms

FDA's warnings to industry "about safety have not always been met adequately or even uniformly accepted," says Steve Tave, director of the agency's dietary supplement programs.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel